British market-research firm Visiongain has forecast a $2.445-billion global market for biosimilars in 2013, a 20-percent increase over 2012, with the fastest growth anticipated in biosimilar monoclonal antibodies and insulins. Biosimilars account for just 2 percent of the overall market for biologics, but the market is evidently expected to grow rapidly in the United States and Europe during the next 10 years as biosimilars currently under development are approved. According to Visiongain pharmaceutical market analyst Richard Lang, “Many companies are interested in entering the biosimilars market. These drugs offer a simpler way to launch biopharmaceuticals, compared with developing novel biologics.” See, May 7, 2013.